NCT05300269
SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2022); last known: Recruiting
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Apr 29, 2022 to Jul 5, 2022
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Timeframe: At week 16, DAY1
Percentage of participants with Pathological complete response ( pCR )
Timeframe: At week 16, DAY1
Secondary (6)
Tumor regression grade ( TRG )
Percentage of participants with R0 Resection ( R0 )
Percentage of participants with Clinical complete response ( cCR ) rate.
Event-free survival ( EFS )
Overall survival ( OS )
Show 1 moreShow less
Disease-free survival ( DFS )
Arms and interventions
Perioperative treatmentExperimental
Eligible subjects will receive standard chemoradiotherapy with SHR-1701 followed by XELOX combined with SHR-1701 and surgery. Adjuvant XELOX combined with SHR-1701 will be given after surgery.
Drugs: SHR-1701;Capecitabine;Oxaliplatin
Sites
1 site in 1 country
- Fudan University Zhongshan HospitalShanghai, Shanghai Municipality, China